Developmental and Reproductive Toxicology Group
Barry S. McIntyre, Ph.D., D.A.B.T.
Group Leader, Developmental & Reproductive Toxicology Group
The Developmental and Reproductive Toxicology Group, headed by Barry McIntyre, Ph.D., D.A.B.T., characterizes the developmental and reproductive toxicity potential of chemicals, herbals, and pharmaceuticals nominated to the NTP for assessment. The group also serves as internal consultants on NTP study design teams, as well as providing perspective relating to reproductive and developmental toxicants to regulatory agencies and the public.
Major Areas of Research
- Utilization of the in vivo study designs (Reproductive Assessment by Continuous Breeding and the Modified One-Generation) to identify reproductive and developmental toxicants. The RACB design is a robust fertility evaluation that goes beyond typical two-generational studies, while the MOG goes makes greater use of F1 offspring for evaluating potential reproductive, developmental, neuro, immune, as well as general toxicities.
- Initiate and coordinate research projects that investigate the mechanisms underlying chemical-mediated reproductive and developmental toxicity.
- Development and refinement of novel assays that identify potential reproductive and developmental toxicants.
- Reproductive and developmental assessments of some:
- Herbal products
- Flame retardants
- Characterizing the potential long-term effects of the sickle cell drug hydroxyurea on male and female reproduction at different life-stages.
- Evaluating Mixtures: Examining how pharmaceuticals and environmental agents can affect the normal developmental pathways and subsequently result in unexpected adverse outcomes.
Barry McIntyre, Ph.D., DABT, a reproductive and developmental toxicologist, leads the Developmental and Reproductive Toxicology Group within the Toxicology Branch of the National Toxicology (NTP) Division. Before joining the Toxicology Branch, he led the US- reproductive and developmental toxicology group at the Schering-Plough Research Institute (now Merck). His group was responsible for conducting non-clinical studies that characterized the potential adverse effects of novel drugs and biologics on development and fertility.
After earning his Ph.D. in Pharmacology/Toxicology from Washington State University in 1997, McIntyre was an NIEHS National Research Service Award Postdoctoral Fellow at the Chemical Industry Institute of Toxicology.